Literature DB >> 21997751

Regulatory watch: leading hedgehog inhibitor submitted for approval as skin cancer drug.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21997751     DOI: 10.1038/nrd3594

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  5 in total

Review 1.  Targeting the Hedgehog pathway in cancer.

Authors:  Lee L Rubin; Frederic J de Sauvage
Journal:  Nat Rev Drug Discov       Date:  2006-12       Impact factor: 84.694

2.  Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened.

Authors:  James K Chen; Jussi Taipale; Michael K Cooper; Philip A Beachy
Journal:  Genes Dev       Date:  2002-11-01       Impact factor: 11.361

3.  Teratogen-mediated inhibition of target tissue response to Shh signaling.

Authors:  M K Cooper; J A Porter; K E Young; P A Beachy
Journal:  Science       Date:  1998-06-05       Impact factor: 47.728

4.  Small molecule modulation of Smoothened activity.

Authors:  James K Chen; Jussi Taipale; Keith E Young; Tapan Maiti; Philip A Beachy
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

5.  Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine.

Authors:  J Taipale; J K Chen; M K Cooper; B Wang; R K Mann; L Milenkovic; M P Scott; P A Beachy
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

  5 in total
  1 in total

Review 1.  Diagnosing the decline in pharmaceutical R&D efficiency.

Authors:  Jack W Scannell; Alex Blanckley; Helen Boldon; Brian Warrington
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.